Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Abstract 4094: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models

Marion Chapellier, Evelina Martinenaite, Preeyam Patel, Lea Svendsen, Shamaila Munir Ahmad, Hannah Jorinde Glöckner, Marco Carretta, Erika Sutanto-Ward, James DuHadaway, Souvik Dey, Shih-Chun Shen, Dema Ghaban, Marcos Iglesias, Megan Biller, Inés Lecoq, Alexander J. Muller, Mads Hald Andersen, Ayako Wakatsuki Pedersen

Cancer Res (2024) 84 (6_Supplement): 4094.

https://doi.org/10.1158/1538-7445.AM2024-4094

Published: 22 March 2024

View article titled, Abstract 4094: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models

Journal Articles

Abstract 3763: IDO vaccine enhances antigen-specific anti-tumor effects by reducing IDO-expressing antigen presenting cells and MDSCs

Rahul Nandre, Vivek Verma, Pankaj Gaur, Pooja Vir, Hua Wang, Baolin Kang, Ayako Wakatsuki Pedersen, Mai-Britt Zocca, Mads Hald Andersen, Seema Gupta, Samir Khleif

Cancer Res (2018) 78 (13_Supplement): 3763.

https://doi.org/10.1158/1538-7445.AM2018-3763

Published: 01 July 2018

View article titled, Abstract 3763: IDO vaccine enhances antigen-specific anti-tumor effects by reducing IDO-expressing antigen presenting cells and MDSCs

Journal Articles

The Balance Players of the Adaptive Immune System

Mads Hald Andersen

Cancer Res (2018) 78 (6): 1379–1382.

https://doi.org/10.1158/0008-5472.CAN-17-3607

Published: 14 March 2018

View article titled, The Balance Players of the Adaptive Immune System

Journal Articles

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Cancer Res (2017) 77 (17): 4562–4566.

https://doi.org/10.1158/0008-5472.CAN-16-3172

Published: 31 August 2017

View article titled, Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Includes: Supplementary data

Journal Articles

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4⁺ T- Cells, Which Dampen CD8⁺ T-cell Antitumor Reactivity

Marco Donia, Rikke Andersen, Julie W. Kjeldsen, Paolo Fagone, Shamaila Munir, Ferdinando Nicoletti, Mads Hald Andersen, Per thor Straten, Inge Marie Svane

Cancer Res (2015) 75 (18): 3747–3759.

https://doi.org/10.1158/0008-5472.CAN-14-2956

Published: 14 September 2015

View article titled, Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

Includes: Supplementary data

Journal Articles

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

Shamaila Munir, Gitte Holmen Andersen, Özcan Met, Marco Donia, Thomas Mørch Frøsig, Stine Kiaer Larsen, Tobias Wirenfeldt Klausen, Inge Marie Svane, Mads Hald Andersen

Cancer Res (2013) 73 (6): 1764–1776.

https://doi.org/10.1158/0008-5472.CAN-12-3507

Published: 14 March 2013

View article titled, HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

Includes: Supplementary data

Journal Articles

Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

Rikke Bæk Sørensen, Tania Køllgaard, Rikke Sick Andersen, Joost Huibert van den Berg, Inge Marie Svane, Per thor Straten, Mads Hald Andersen

Cancer Res (2011) 71 (6): 2038–2044.

https://doi.org/10.1158/0008-5472.CAN-10-3403

Published: 14 March 2011

View article titled, Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

Includes: Supplementary data

Journal Articles

The Paradoxical Association between Bcl-2 Expression and Prognosis: Does the Immune System Make the Difference?

Jürgen C. Becker, Per thor Straten, Mads Hald Andersen

Cancer Res (2005) 65 (7): 2983.

https://doi.org/10.1158/0008-5472.CAN-05-0092

Published: 01 April 2005

View article titled, The Paradoxical Association between Bcl-2 Expression and Prognosis: Does the Immune System Make the Difference?

Journal Articles

Immunogenicity of Constitutively Active ^V599EBRaf

Mads Hald Andersen, Joachim Fensterle, Selma Ugurel, Sine Reker, Roland Houben, Per Guldberg, Thomas G. Berger, Dirk Schadendorf, Uwe Trefzer, Eva-B. Bröcker, Per thor Straten, Ulf R. Rapp, Jürgen C. Becker

Cancer Res (2004) 64 (15): 5456–5460.

https://doi.org/10.1158/0008-5472.CAN-04-0937

Published: 02 August 2004

View article titled, Immunogenicity of Constitutively Active V599EBRaf

Journal Articles

Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients

Mads Hald Andersen, Lars Ø. Pedersen, Barbara Capeller, Eva-Bettina Bröcker, Jürgen C. Becker, Per thor Straten

Cancer Res (2001) 61 (16): 5964–5968.

Published: 01 August 2001

View article titled, Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients

Journal Articles

Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients

Mads Hald Andersen, Lars Østergaard Pedersen, Jürgen C. Becker, Per thor Straten

Cancer Res (2001) 61 (3): 869–872.

Published: 02 February 2001

View article titled, Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients

Journal Articles

Oligoclonal T-Cell Receptor Usage of Melanocyte Differentiation Antigen-reactive T Cells in Stage IV Melanoma Patients

David Schrama, Mads Hald Andersen, Patrick Terheyden, Louise Schrøder, Lars Østergaard Pedersen, Per thor Straten, Jürgen C. Becker

Cancer Res (2001) 61 (2): 493–496.

Published: 01 January 2001

View article titled, Oligoclonal T-Cell Receptor Usage of Melanocyte Differentiation Antigen-reactive T Cells in Stage IV Melanoma Patients

NARROW

Abstract 4094: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models

Abstract 3763: IDO vaccine enhances antigen-specific anti-tumor effects by reducing IDO-expressing antigen presenting cells and MDSCs

The Balance Players of the Adaptive Immune System

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4⁺ T- Cells, Which Dampen CD8⁺ T-cell Antitumor Reactivity

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

The Paradoxical Association between Bcl-2 Expression and Prognosis: Does the Immune System Make the Difference?

Immunogenicity of Constitutively Active ^V599EBRaf

Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients

Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients

Oligoclonal T-Cell Receptor Usage of Melanocyte Differentiation Antigen-reactive T Cells in Stage IV Melanoma Patients

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only